

191/LG/SE/SEPT/2023/GBSL

September 11, 2023

To,  
**BSE Limited,**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort, Mumbai - 400 001  
**Scrip Code: 509079**

To,  
**National Stock Exchange of India Limited**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai - 400 051  
**Scrip Symbol: GUFICBIO**

Dear Sir/Madam,

**Sub.: Press Release - Gufic receives approval of TGA, Australia and ANVISA, Brazil for Parecoxib 40mg injection**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed herewith a press release being issued by the Company on the captioned subject, the contents of which is self-explanatory.

The same is submitted for public dissemination and for your record.

Thanking You,

Yours truly,

**For Gufic Biosciences Limited**

**Ami Shah**  
**Company Secretary & Compliance Officer**  
**Membership No. A39579**

**Encl.: As above**



## **GUFIC RECEIVES TGA AUSTRALIA AND ANVISA BRAZIL APPROVAL FOR PARECOXIB 40MG INJECTION**

Gufic Biosciences Limited (Gufic) have received approval from the Therapeutic Group Administration (TGA), Australia and the National Health Surveillance Agency (ANVISA), Brazil for Parecoxib Sodium 40mg Lyophilized Powder for Injection, a selective COX-2 inhibitor, which shall be used for short-term treatment of acute pain and post-operative pain in adult patients.

Gufic has been persistently committed to saving and improving lives of patients across the globe with its continuous efforts through the international regulatory agencies to bring novel molecules for the mankind.

### **About Parecoxib**

Parecoxib Sodium is the first parenteral selective COX-2 inhibitor available for clinical use in pain management. Selective COX-2 inhibitors were developed to avoid the gastrointestinal side effects related to COX-1 inhibitors. Parecoxib is a prodrug of a sulphonamide based COX-2 inhibitor, Valdecoxib, a potent anti-inflammatory and analgesic drug. Following a single Intravenous (IV) or Intramuscular (IM) dose, Parecoxib is rapidly converted to Valdecoxib by enzymatic hydrolysis in Liver.

Parecoxib's first perceptible analgesic effect occurs within seven to thirteen minutes, with a peak effect within two hours following administration of single dose of 40mg injection by IV or IM route.

Parecoxib has more potent synergistic effects when combined with morphine than other COX-2 NSAIDs and reduces the amount of opioid needed for adequate analgesia. This overall reduction in opioid drug improves the safety margin of the analgesic regime and provides better analgesic coverage.

### **About Gufic**

Gufic is engaged in the Research and Development, manufacturing, marketing, distribution and sale of pharmaceutical and allied products. Gufic is known and respected for innovative and high quality pharmaceutical and Herbal products along with a wide range of Active Pharmaceutical Ingredients (APIs). Gufic is one of the fastest growing company among the top 100 pharma companies in India and is also one of the largest manufacturers of Lyophilized injections in India having a fully automated lyophilization plant. The lyophilized products are available in Therapeutic areas like Antibiotic, Antifungal, Cardiac, Infertility, Antiviral and Proton-Pump Inhibitor (PPI). Gufic is now augmenting its global focus by deepening the presence in the priority markets of India, Australia, Brazil, Germany, Switzerland, South Africa, Russia, Canada, Europe and other key countries within the emerging market territories. Gufic aims at providing lifesaving drugs to people at affordable prices with no compromise in its quality. Gufic is a WHO-GMP, EU GMP, ANVISA Brazil, Russian GMP, Health Canada, Ukraine GMP, Australia TGA, Colombia INVIMA and Uganda NDA approved company with a total capacity of 48 million lyophilized vials per annum.